Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients

Launched by VIDYA THERAPEUTICS INC · Jul 17, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new medicine called VT7208 to see if it is safe and well-tolerated in both healthy people and those with Multiple Sclerosis (MS). The study has three parts: first, it will look at how the medicine behaves in the body and how safe it is in healthy volunteers; second, it will check how food affects the medicine in healthy volunteers; and third, it will test the safety of the medicine in people who have MS.

To take part, healthy volunteers need to be between 18 and 65 years old, in good health, and willing to follow the study rules, which include having a lumbar puncture—a procedure where a small amount of spinal fluid is collected. People with MS can join if they are between 18 and 60 years old, have a confirmed MS diagnosis, and are also in good health. Participants will need to attend all study visits and agree to the lumbar puncture as part of the study. The trial is not recruiting yet, and certain health conditions or recent blood donations may prevent someone from joining. Overall, this study aims to learn more about VT7208’s safety and how it works in the body, which could help develop new treatments for MS in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Parts 1 and 2
• • Age 18-65
• • Must be in good health with no significant medical history
• • Willing and able to attend all study visits and comply with study requirements, including lumbar puncture for CSF collection
• • Able and willing to provide written informed consent
• • Part 3
• • Age 18-60
• • Must be in good health with no significant medical history
• • MS diagnosis prior to Day 1 in accordance with 2017 McDonald criteria.
• • Willing and able to attend all study visits and comply with study requirements, including lumbar puncture for CSF collection
• • Able and willing to provide written informed consent
• Exclusion Criteria:
• • Evidence of clinically significant condition or disease
• • Any physical or psychological condition that prohibits study completion
• • Known history of illicit drug use or drug abuse, harmful alcohol use (at the -Investigator's discretion), alcoholism, and/or smoking or nicotine-containing product use within 7 days prior to the first dose of study agent
• • History of severe allergic reactions or hypersensitivity
• • Donation or loss of ≥ 1 unit of whole blood or plasma within 4 weeks prior to dosing